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In both murine and human systems, incubation of fresh lymphocytes alone in
lectin-free lymphokine preparations rich in interleukin 2 (IL-2) results in the
development of lytic activity against fresh autologous and allogeneic solid tumor
cells (1-4) . The human lymphokine-activated killer cells (LAK) represent a
cytotoxic system distinct from conventional cytotoxic T lymphoid cells and
natural killer (NK) cells based on a variety of characteristics including kinetics of
activation, target cell specificity, the stimulus responsible for activation, and
phenotype of the precursor and effector cells (2-5) .
While we have consistently observed LAK activation only after incubation of
PBL with cytokine preparations containing IL-2, it was possible that due to the
heterogeneous nature of our standard lectin-free IL-2 preparations, other lym-
phokine(s) or monokine(s) could be responsible or could act synergistically with
IL-2 to activate LAK. Therefore, this study was undertaken to define the
cytokine(s) responsible for the direct activation of nonlytic PBL into LAK cells .
The results show that the LAK stimulus adsorbs significantly to IL-2-dependent
murine cell lines, as does all detectable IL-2 activity . IL-2 preparations from both
the Jurkat leukemia line (6, 7), and from the MLA-144 line (8) purified to
apparent molecular homogeneity were both highly active in the generation of
LAK. Anti-Tac antibody that recognizes the IL-2 receptor (9, 10) was observed
to block LAK activation . Purified preparations of IL-1, migration inhibition
factor (MIF), interferon (IFN), and IFN-y produced by recombinant DNA
technology were all negative for activation of LAK. Thus, we conclude that IL-
2 alone directly activates LAK precursors into cytolytic effector cells that are
efficient in lysing single-cell suspensions of noncultured solid tumor cells in a 4-
h chromium-release assay .
Materials and Methods
IL-2 Preparations and Purification .
￿
Lymphokine supernatants rich in IL-2 activity were
prepared by stimulation of human PBL with phytohemagglutinin (PHA) as described in
detail previously (11, 12) . The crude IL-2 preparation was then partially purified accord-
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ing to the procedure of Meir and Gallo (13), and was used as the starting material for the
IL-2 adsorption studies reported in Fig. 1 .
IL-2 from the Jurkat human leukemia line (14) was obtained after stimulation with
PMA and PHA as described (15). Jurkat IL-2 was purified using adsorption to an anti-IL-
2 affinity column using a murine monoclonal antibody (16). The IL-2 that was eluted
from the column appeared homogeneous by two-dimensional gel electrophoresis using
isoelectric focusing (IEF) in the first dimension, followed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (16).
IL-2 purified from the cultured supernatant of the Gibbon ape MLA-144 was the
generous gift of Dr. Louis Henderson and Dr. Harvey Rabin, Frederick Cancer Research
Center, Frederick, MD. MLA IL-2 was purified to apparent molecular homogeneity by
trimethylsilane-controlled pore glass adsorption, followed by reverse-phase high perform-
ance liquid chromatography as described by Henderson et al. (17). All lymphokine
preparations were tested for IL-2 content by their ability to stimulate ['H]thymidine
uptake in a 48-h assay using human IL-2-dependent cell lines as previously described (11,
12).
Adsorption ofHuman IL-2 by IL-2-dependent Lymphocyte Lines.
￿
IL-2-addicted murine cells
(line 53) were harvested, washed free of culture medium, and incubated at 37°C for 2 h
in RPMI 1640 medium (5 X 106 cells/ml) containing 10% human AB serum (CM). These
cells were then washed twice in serum-free RPMI 1640 and divided into aliquots of 5 X
10' each. 1 ml of a dilution of human IL-2 in RPMI 1640 was added to each aliquot of
line 53 cells, and adsorption performed at room temperature for 2 h with occasional
mixing. This first adsorption was terminated by centrifugation of the cells, after which
the supernatant was aspirated and added to a second 5 X 10' cell pellet for an additional
adsorption step.
Preparation and Purification ofOther Cytokines.
￿
Human IL-1 was prepared from Ficoll-
Hypaque-purified PBL by culturing for 48 h at 3 X 106/ml in minimal essential medium
containing 5% pooled normal human serum and 10 jLg/ml Escherichia coli lipopolysaccha-
ride (LPS) (Difco Laboratories Inc., Detroit, MI). IL-1 was purified by hollow fiber
diafiltration and ultrafiltration, followed by sucrose gradient IEF, and activity was deter-
mined in the mouse thymocyte [5H]thymidine incorporation assay as previously described
(18). The IEF-purified material expressed biological activity at 0.1% (vol/vol) and con-
tained no IL-2 activity.
Two preparations of leukocyte MIT devoid of IL-2 were the generous gift of Dr. H .
Verheul, Organon, OSS, Holland (19) and represent the supernatant of human lympho-
bastoid cell line cultures CP 82004 and 82DB02. The specific MIF activity was 36 and 17
U/mg, respectively. IFN-y produced by recombinant DNA technology was generously
provided by Genentech, Inc., San Francisco, CA. Purified alpha and gamma IFN produced
from PBL was purchased from Interferon Sciences, Inc., New Brunswick, NJ.
LAK Activation and Testing for Cytotoxicity.
￿
PBL at 1 X 106/ml were cultured in CM
containing 10% human AB serum (10 ml maximum) for 4-6 d at 37°C with various
dilutions of IL-2 or other factors in Costar 3050 flasks (Costar, Cambridge, MA). The
cells were then harvested, washed twice in CM, counted, and used as effector cells for
lysis of NK-resistant, cryopreserved, uncultured sarcoma cells. These cells were composed
of a minimum of 93% tumor cells as judged by cytological analysis (3). Lysis was tested in
a 4-h
51 Cr-release assay at a variety of effector/target ratios and data is reported as either
percent specific lysis (2) or in terms of lytic units (LU), defined as the number of effector
cells required to cause a 33 .3% lysis of 5 X 105 tumor cells.
Results and Discussion
LAK Activation Signal(s) Copurfies with IL-2 During Protein Purification Proce-
dures. Since LAK stimulation always occurred when IL-2-rich lymphokine
supernatants were used, our initial approach to dissection of the signal(s) respon-
sible for LAK activation was to apply the standard IL-2 purification procedure1358
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and follow in parallel the separation of IL-2 and LAK activation factor(s). We
consistently observed LAK activation using IL-2-enriched fractions from am-
monium sulfate precipitation and DEAE anion exchange chromatography. Fur-
thermore, we previously reported (20) that these two activities copurified during
ACA 54 Ultragel separation, confirming that IL-2 and the LAK stimulatory
signal(s) share similar physical properties ofmolecular size (used in ACA Ultragel
separation) and ionic/hydrophobic characteristics (used in DEAEanion exchange
chromatography).
LAKSti)nulatory Signal Adsorbsto IL-2-dependent Cells.
￿
Fig. 1 displays the results
from one of three adsorption experiments in which the lectin-free, partially
purified IL-2 and the LAK stimulatory signal(s) were consistently adsorbed by
IL-2-dependent cell lines. Adsorption was effective in removing all IL-2 activity
and in causing a 4-16-fold decrease in the generation of LAK activity measured
in LU.
LAK Activation is Inhibited by Monoclonal Anti-IL-2-receptor Antibodies. The
monoclonal antibody, anti-Tac, has been reported to recognize the IL-2 receptor
and block IL-2 binding (9, 10). When dilutions of anti-Tac ascites (generously
provided by Dr. Thomas Waldmann, Metabolism Branch, National Cancer
Institute) were added to the initiation of LAK culture on day 0 at the same time
as the partially purified lectin-free IL-2, a dose-dependent inhibition of LAK
activation was observed (Table I). In contrast, addition of anti-Tac to the 4-h
cytotoxicity test had no effect, even at the 1 :500 dilution. Therefore, the anti-
Tac antibody appeared to inhibit the activation phase of LAK, implying that the
binding of IL-2 to its receptors is an obligatory step in LAK cell activation .
Purified IL-2 Activates LAK. The preceding data provides very strong yet
circumstantial evidence that LAK cells are stimulated directly by IL-2. To test
this in a conclusive manner, two preparations of IL-2 purified to molecular
homogeneity were used. Both theJurkat-derived (16) and MLA-144-derived IL-
2 were highly stimulatory for LAK over a very broad concentration range (Table
II).
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Adsorption of IL-2 and LAK stimulatory activities by IL-2-dependent cell lines.
IL-2 was adsorbed as described in Materials and Methods. Pre- and post-adsorption samples
were tested for IL-2 content (A) and for LAKstimulation (B).'H-tdr, ['Hlthymidine.GRIMM ET AL.
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Though we have confirmed that highly purified IL-2 directly activates LAK
cells, IL-2 may not be exclusive in this property. Therefore, we have acquired
and tested a number of other human cytokines that are able to stimulate
mononuclear cell functions. IL-1, MIF, and a variety ofIFN preparations tested
at several log-fold dilutions surrounding the optimal dose (optimal dose deter-
mined independentlyfor each cytokine preparation; data not shown) were unable
to generate LAK activity when incubated with fresh PBM. Atlhough IFN are
known to augment suboptimal NK activity, aswell as being produced in response
to IL-2, we found them unable to directly convert noncytolytic LAK precursors
into cytolytic cells active against NK-resistant tumors.
IL-2 was reported originally not to be stimulatory for nonactivated lympho-
cytes because in a 2-d [3H]thymidine-uptake assay, the stimulation is negligible
relative to IL-2-dependent cells. Lectin-free IL-2 preparations, however, do
cause detectable [3H]thymidine uptake above the level in control cultures and
can be used to initiate long-term growth from these nonactivated populations
(11, 12). Direct activation of PBL into LAK cells by purified IL-2 suggests that
receptors for IL-2 are expressed _on some PBL. Additional evidence for the
existence ofIL-2 receptors on PBL is suggested by the radiolabeled IL-2-binding
studies of Robb et al. (7) in which a low number (-210/cell) of receptors was
found on resting PBL.
The exact nature of the LAK precursor is still not understood. It was possible
that the LAK precursors were the multiclonal memory T cells that may be
circulating in the PBL, since it is known that secondary cytotoxic T lymphocytes
(CTL) can be generated from memory Tcells directly by IL-2 (5). However, the
LAK precursors did not express the serologic phenotype of memory CTL, when
tested in parallel with allospecific memory CTL generated in vitro (5). TheseTe-
sults imply that two subpopulations of PBL may respond directly to IL-2: the
memory CTL, which express a Tcell phenotype, and the LAK precursors, which
do not.
Summary
Purified interleukin 2 (IL-2) was found to be sufficient for direct activation of
peripheral blood lymphocytes into lymphokine-activated killer (LAK) cells. The
LAK activation factor was directly and consistently associated with IL-2 activity
TABLE I
Inhibition ofLAK Development by Anti-Tac
* Anti-Tac was added at the initiation of cultures of PBL with IL-2. After 5 d of
incubation, the cells were harvested, counted, and tested for lysis of fresh sarcoma
tumor target cells at a variety of effector/target ratios. The cell recoveries in the
cultures containing anti-Tac were from 50 to 88% ofthe control:culture.
$ LU were calculated by extrapolating the number ofeffector cells required to cause
a 33.3% lysis of 5 x 10s tumor cells.
Anti-Tac dilution
LAG generated (LU/106
cells Percent inhibition
0 111 -
1 :16,000 71 36
1 :4,000 25 77
1 :2,000 17 85
1 :1,000 13 89
1 :500 5 961360
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TABLE 11
Activation ofLAK by Lymphokines
* See Materials and Methods for the complete reference for each cytokine.
$ Each cytokine was tested at the maximal concentration available, and at least four dilutions lower, covering the
optimal range of its inherent activity (data not shown) .
(See Materials and Methods) are reported for the highest LAK activity observed toward the NK-resistant sarcoma
tumor target cell .
using classic protein purification techniques, adsorption to IL-2-dependent cell
lines, and inhibition with anti-Tac antibody . As yet, no other cytokines have
been found that perform the same role .
Receivedfor publication 19May 1983 and in revisedform 2 August 1983.
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